TY - JOUR
T1 - Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma
AU - Hesselink, Marielle S. Klein
AU - Bocca, Gianni
AU - Hummel, Yoran M.
AU - Brouwers, Adrienne H.
AU - Burgerhof, Johannes G. M.
AU - van Dam, Eveline W. C. M.
AU - Gietema, Jourik A.
AU - Havekes, Bas
AU - van den Heuvel-Eibrink, Marry M.
AU - Corssmit, Eleonora P. M.
AU - Kremer, Leontien C. M.
AU - Netea-Maier, Romana T.
AU - van der Pal, Helena J. H.
AU - Peeters, Robin P.
AU - Plukker, John T. M.
AU - Ronckers, Cecile M.
AU - van Santen, Hanneke M.
AU - van der Meer, Peter
AU - Links, Thera P.
AU - Tissing, Wim J. E.
PY - 2017/12
Y1 - 2017/12
N2 - Introduction: Whether pediatric patients with differentiated thyroid carcinoma (DTC) are at risk of developing treatment-related adverse effects on cardiac function is unknown. We therefore studied in long-term survivors of pediatric DTC the prevalence of cardiac dysfunction and atrial fibrillation in relation to treatment variables, and the association between cardiac dysfunction and plasma biomarkers. Methods: In this nationwide prospective multicenter study, cardiac assessments were performed in 66 adult survivors of pediatric DTC (age at diagnosis 18 years and follow-up 5 years after diagnosis) treated in the Netherlands between 1970 and 2009. Assessment included echocardiography, plasma biomarkers (N-terminal pro-brain natriuretic peptide, high-sensitive troponin-T, galectin-3), and 24-hour Holter electrocardiography. Echocardiographic measurements were compared with retrospective data of 66 sex- and age-matched unaffected Dutch controls. Diastolic dysfunction was defined as an early diastolic septal and/or lateral tissue velocity (e) less than 2 SD of mean age-adjusted reference data. Results: The survivors (86.4% women) had at DTC diagnosis a median age of 16 years. Median follow-up was 17 years. Left ventricular ejection fraction
AB - Introduction: Whether pediatric patients with differentiated thyroid carcinoma (DTC) are at risk of developing treatment-related adverse effects on cardiac function is unknown. We therefore studied in long-term survivors of pediatric DTC the prevalence of cardiac dysfunction and atrial fibrillation in relation to treatment variables, and the association between cardiac dysfunction and plasma biomarkers. Methods: In this nationwide prospective multicenter study, cardiac assessments were performed in 66 adult survivors of pediatric DTC (age at diagnosis 18 years and follow-up 5 years after diagnosis) treated in the Netherlands between 1970 and 2009. Assessment included echocardiography, plasma biomarkers (N-terminal pro-brain natriuretic peptide, high-sensitive troponin-T, galectin-3), and 24-hour Holter electrocardiography. Echocardiographic measurements were compared with retrospective data of 66 sex- and age-matched unaffected Dutch controls. Diastolic dysfunction was defined as an early diastolic septal and/or lateral tissue velocity (e) less than 2 SD of mean age-adjusted reference data. Results: The survivors (86.4% women) had at DTC diagnosis a median age of 16 years. Median follow-up was 17 years. Left ventricular ejection fraction
KW - differentiated thyroid carcinoma
KW - pediatric patients
KW - late effects
KW - cancer survivors
KW - diastolic dysfunction
KW - EXOGENOUS SUBCLINICAL HYPERTHYROIDISM
KW - CHILDHOOD-CANCER
KW - HEART-FAILURE
KW - ASSOCIATION GUIDELINES
KW - MANAGEMENT GUIDELINES
KW - ADULT SURVIVORS
KW - ECHOCARDIOGRAPHY
KW - RECOMMENDATIONS
KW - SUPPRESSION
KW - HORMONE
U2 - 10.1089/thy.2017.0383
DO - 10.1089/thy.2017.0383
M3 - Article
C2 - 29132262
SN - 1050-7256
VL - 27
SP - 1481
EP - 1489
JO - Thyroid
JF - Thyroid
IS - 12
ER -